Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone609-359-3020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$63.55 million
Profitability
Miscellaneous
Employees165
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions
What is Antares Pharma's stock symbol?
Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."
How were Antares Pharma's earnings last quarter?
Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings results on Thursday, February, 28th. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.06. The specialty pharmaceutical company had revenue of $18.82 million for the quarter, compared to analyst estimates of $18.36 million. Antares Pharma had a negative net margin of 10.25% and a negative return on equity of 22.42%. View Antares Pharma's Earnings History.
When is Antares Pharma's next earnings date?
What guidance has Antares Pharma issued on next quarter's earnings?
Antares Pharma updated its FY 2019 earnings guidance on Thursday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95-105 million, compared to the consensus revenue estimate of $104.88 million.
What price target have analysts set for ATRS?
5 equities research analysts have issued 1 year price objectives for Antares Pharma's shares. Their forecasts range from $1.99 to $8.00. On average, they anticipate Antares Pharma's share price to reach $4.8280 in the next twelve months. This suggests a possible upside of 77.5% from the stock's current price. View Analyst Price Targets for Antares Pharma.
What is the consensus analysts' recommendation for Antares Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.
Has Antares Pharma been receiving favorable news coverage?
Press coverage about ATRS stock has been trending somewhat positive on Sunday, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Antares Pharma earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
Who are some of Antares Pharma's key competitors?
Some companies that are related to Antares Pharma include Irhythm Technologies (IRTC), Atrion (ATRI), Mazor Robotics (MZOR), K2M Group (KTWO), Cardiovascular Systems (CSII), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX), Tactile Systems Technology (TCMD), Intersect ENT (XENT), Shockwave Medical (SWAV), Cerus (CERS), AngioDynamics (ANGO) and OraSure Technologies (OSUR).
What other stocks do shareholders of Antares Pharma own?
Who are Antares Pharma's key executives?
Antares Pharma's management team includes the folowing people:
- Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
- Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
- Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
- Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)
- Edward Kessig, VP of Sales
Who are Antares Pharma's major shareholders?
Antares Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Mycio Wealth Partners LLC (1.01%) and Quantitative Systematic Strategies LLC (0.01%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.
Which major investors are selling Antares Pharma stock?
ATRS stock was sold by a variety of institutional investors in the last quarter, including Mycio Wealth Partners LLC and Quantitative Systematic Strategies LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Robert F Apple. View Insider Buying and Selling for Antares Pharma.
How do I buy shares of Antares Pharma?
Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Antares Pharma's stock price today?
One share of ATRS stock can currently be purchased for approximately $2.72.
How big of a company is Antares Pharma?
Antares Pharma has a market capitalization of $436.64 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.
What is Antares Pharma's official website?
How can I contact Antares Pharma?
Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]
MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
